Skip to main content

Advertisement

SpringerLink
Log in

Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting

  • Reproductive Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

The use of cabergoline and coasting are both effective in reducing the risk of ovarian hyperstimulation syndrome (OHSS). Our aim was to compare the effectiveness of cabergoline with coasting to prevent moderate–severe OHSS.

Methods

Fifty-seven consecutive infertile patients (81 cycles) at risk of developing OHSS were enrolled through our computerized IVF database system. Inclusion criteria were: (i) E2 level on the day of human chorionic gonadotrophin (hCG) greater than 3,500 pg/ml; (ii) patients who underwent luteal long GnRH agonist cycle; (iii) patients who used cabergoline for OHSS prevention; (iv) patients who underwent coasting for OHSS prevention. The cabergoline group constituted 17 patients (26 cycles) who started using 0.5 mg oral cabergoline daily for 8 days on the day of hCG, whereas the coasting group constituted 40 patients (55 cycles) who underwent coasting.

Results

Both groups were comparable regarding the women’s mean age, body mass index and duration of infertility. Implantation rate, clinical pregnancy per embryo transfer and miscarriage rates were not different between the two groups. There was no OHSS in the cabergoline group (0 %), whereas there were two OHSS (3.6 %) in the coasting group; however, this difference was not significant.

Conclusions

In conclusion, 0.5 mg daily use of cabergoline for 8 days beginning from hCG administration is a very effective way to reduce moderate–severe OHSS without sacrificing pregnancy rates in patients at risk of developing OHSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aboulghar M (2009) Symposium: update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online 19:33–42

    Article  PubMed  CAS  Google Scholar 

  2. Aboulghar M, Evers JH, Al-Inany H (2002) Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 17:3027–3032

    Article  PubMed  CAS  Google Scholar 

  3. Al-Shawaf T, Zosmer A, Hussain S et al (2001) Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified ‘coasting’ strategy based on ultrasound for identification of high-risk patients. Hum Reprod 16:24–30

    Article  PubMed  CAS  Google Scholar 

  4. Alvarez C, Alonso-Muriel I, Garcia G et al (2007) Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22:3210–3214

    Article  PubMed  CAS  Google Scholar 

  5. Alvarez C, Marti-Bonmati L, Novella-Maestre E et al (2007) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931–2937

    Article  PubMed  CAS  Google Scholar 

  6. Barash A, Weissman A, Manor M et al (1998) Prospective evaluation of endometrial thickness as a predictor of pituitary down-regulation after gonadotropin-releasing hormone analogue administration in an in vitro fertilization program. Fertil Steril 69:496–499

    Article  PubMed  CAS  Google Scholar 

  7. Bukulmez O, Yarali H, Yucel A et al (2000) Intracytoplasmic sperm injection versus in vitro fertilization for patients with a tubal factor as their sole cause of infertility: a prospective, randomized trial. Fertil Steril 73:38–42

    Article  PubMed  CAS  Google Scholar 

  8. Carizza C, Abdelmassih V, Abdelmassih S et al (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17:751–755

    Article  PubMed  CAS  Google Scholar 

  9. Egbase PE, Sharhan MA, Grudzinskas JG (1999) Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 14:1421–1425

    Article  PubMed  CAS  Google Scholar 

  10. Faul F, Erdfelder E, Buchner A et al (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149–1160

    Article  PubMed  Google Scholar 

  11. Garcia-Velasco JA, Isaza V, Quea G et al (2006) Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril 85:547–554

    Article  PubMed  CAS  Google Scholar 

  12. Garcia-Velasco JA, Pellicer A (2003) New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 15:251–256

    Article  PubMed  Google Scholar 

  13. Hwang JL, Lin YH, Seow KM (2010) Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels. Int J Gynaecol Obstet 108:159–160

    Article  PubMed  CAS  Google Scholar 

  14. Kol S, Solt I (2008) GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J Assist Reprod Genet 25:63–66

    Article  PubMed  CAS  Google Scholar 

  15. Ludwig M, Bauer O, Lopens A et al (1998) Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. Hum Reprod 13:30–32

    Article  PubMed  CAS  Google Scholar 

  16. Mansour R, Aboulghar M, Serour G et al (2005) Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 20:3167–3172

    Article  PubMed  Google Scholar 

  17. Nargund G, Hutchison L, Scaramuzzi R et al (2007) Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 14:682–685

    Article  PubMed  CAS  Google Scholar 

  18. Rimington MR, Walker SM, Shaw RW (1997) The use of laparoscopic ovarian electrocautery in preventing cancellation of in vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod 12:1443–1447

    Article  PubMed  CAS  Google Scholar 

  19. Rizk B, Aboulghar M, Smitz J et al (1997) The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3:255–266

    Article  PubMed  CAS  Google Scholar 

  20. Sher G, Zouves C, Feinman M et al (1995) ‘Prolonged coasting’: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Hum Reprod 10:3107–3109

    PubMed  CAS  Google Scholar 

  21. Sohrabvand F, Ansaripour S, Bagheri M et al (2009) Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. Int J Fertil Steril 3:35–40

    Google Scholar 

  22. Tang H, Hunter T, Hu Y et al (2012) Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2:CD008605

    PubMed  Google Scholar 

  23. Ulug U, Bahceci M, Erden HF et al (2002) The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 17:310–313

    Article  PubMed  Google Scholar 

  24. Waldenstrom U, Kahn J, Marsk L et al (1999) High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by ‘prolonged coasting’ of very hyperstimulated patients: a multicentre study. Hum Reprod 14:294–297

    Article  PubMed  CAS  Google Scholar 

  25. Youssef MA, van Wely M, Hassan MA et al (2010) Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 16:459–466

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Ibrahim Esinler & Gurkan Bozdag

  2. Department of Histology and Embryology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Lale Karakocsokmensuer

Authors
  1. Ibrahim Esinler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gurkan Bozdag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lale Karakocsokmensuer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim Esinler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esinler, I., Bozdag, G. & Karakocsokmensuer, L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet 288, 1159–1163 (2013). https://doi.org/10.1007/s00404-013-2875-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2875-z

Keywords

Search

Navigation